- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02878278
Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect,Pharmacokinetics, Pharmacodynamics and EB Virus Activation
Research About the Differences Between Chidamide Taken Daily and Twice a Week in Pharmacokinetics
- To compare the therapeutic effects, safety and the corresponding pharmacokinetics and pharmacodynamics between two different method of drug administration: 10mg, daily and 30mg/d, twice every week, and find out the more effect way of Chidamide administration.
- To examine whether Chidamide could activate EB virus, and whether the above two different ways of administration are different in EB virus activation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Currently, Chidamide is taken twice a week, this comes from cell experiment and phase I clinical trial, which showed that the de-acetylation effect of Chidamide could last for 72 hours after administration. However, daily administration of Chidamide may create a more steady Chidamide concentration, thus improve the de-acetylation effect of Chidamide, so it's necessary to compare the two different ways of administration.
Current study showed that Romidepsin, a HDACI, could activate EBV during the treatment of NKTCL, whether Chidamide, as a novel HDACI, could activate EBV is still not clear, so this problem is worth to be accessed.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Huiqiang Huang, Professor
- Email: huanghq@sysucc.org.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- NKTCL patients confirmed by histopathology examination.
- Age 18-75 years old, male or female, fertile women should have effective contraceptive measures.
- NT/T cell lymphoma patients with disease progression or non-remission after L-asparaginase treatment or L-asparaginase-contained regimen treatment. Non-remission is defined as: patients do not have partial remission (PR) or better responses after treated by L-asparaginase contained regimen.
- Patients who had 1-3 regimens (including chemotherapy, stem cell transplantation), but did not achieve remission or relapsed after remission.
- With at least 1 measurable focus, whose long diameter ˃ 1.5cm, short diameter ˃1.0cm, or at least one evaluable focus.
- Body weight: male 67±20 kilograms (47-87 kg), female 55±20 kilograms (35-75 kg);
- Blood-routine test within 14 days of enrollment should satisfy (except lymphoma-related abnormalities): Hb≥80g/L,ANC≥1.0×109/L,PLT≥75×109/L;
- ECOG: 0-2;
- Estimated survival ≥ 3 months;
- Willing to sign the written consent before the trial.
Exclusion Criteria:
- Women during pregnancy or lactation, or fertile women unwilling to take contraceptive measures.
- QTc elongation with clinical significance ( male˃ 450ms, female˃ 470ms), ventricular tachycardia, atrial fibrillation, cardiac conducting blockage, myocardial infarction within 1 year, congestive heart failure, symptomatic coronary heart disease that requires treatment.
- Cardiac B ultrasound show end-diastolic pericardial dark zone≥ 10cm
- Patients who have received organ transplantation.
- Patients received symptomatic treatment for bone marrow toxicity within 7 days prior to enrollment.
- Patients with active hemorrhage.
- Patients with or with history of thrombosis, embolism, cerebral hemorrhage, or cerebral infarction.
- Patients with active infection, or with continuous fever within 14 days prior to enrollment.
- Had major organ surgery within 6 weeks prior to enrollment.
- Abnormal blood routine test results within 14 days prior to enrollment (Hb˂80g/L,ANC˂1.0×109/L,PLT˂75×109/L; Impaired liver function ( Total bilirubin ˃ 1.5 times of normal maximum, ALT/AST˃ 2.5 times of normal maximum, for patients with infiltrative liver disease ALT/AST ˃ 5 times of normal maximum), impaired renal function (serum creatinin˃ 1.5 times of normal maximum).
- Patients with history of Chidamide treatment and had disease progression within 6 months afterward;
- Patients that received large dose of steroids (˃10mg/d dexamethasone or other steroids of the equivalent dosage) within 4 weeks prior to enrollment;
- Patients with hemophagocytic syndrome;
- Patients with central nerve system diseases or history of central nerve system diseases;
- Patients with mental disorders or those do not have the ability to consent;
- Patients that had been enrolled in other clinical trials within 3 months prior to enrollment;
- Patients with drug abuse, long term alcoholism that may impact the results of the trial.
- Non-appropriate patients for the trial according to the judgment of the investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chidamide BIW
Chidamide is given 30mg,5mg/pill,twice a week, for at least 6 weeks
|
Chidamide is given 30mg, twice a week
Other Names:
|
Experimental: Chidamide QD
Chidamide is given 10mg,5mg/pill, everyday,for at least 6 weeks.
|
Chidamide is given 10mg,QD
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Response Rate (ORR)
Time Frame: through study completion, an average of 30 months
|
through study completion, an average of 30 months
|
Duration of Response (DOR)
Time Frame: through study completion, an average of 30 months
|
through study completion, an average of 30 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression Free Survival (PFS)
Time Frame: through study completion, an average of 30 months
|
through study completion, an average of 30 months
|
Overall Survival (OS)
Time Frame: through study completion, an average of 30 months
|
through study completion, an average of 30 months
|
EBV-DNA
Time Frame: through study completion, an average of 30 months
|
through study completion, an average of 30 months
|
EBV-antibodies
Time Frame: through study completion, an average of 30 months
|
through study completion, an average of 30 months
|
white blood cell count
Time Frame: every week though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every week though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
red blood cell count
Time Frame: every week though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every week though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
blood Hb level
Time Frame: every week though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every week though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
blood platelet count
Time Frame: every week though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every week though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
vital signs
Time Frame: every week though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every week though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
Serum alanine aminotransferase level
Time Frame: every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
Serum aspartate transaminase level
Time Frame: every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
Serum total bilirubin level
Time Frame: every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
Serum direct bilirubin level
Time Frame: every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
Serum indirect bilirubin level
Time Frame: every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
Serum glutamyltranspeptidase level
Time Frame: every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
Serum albumin level
Time Frame: every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
Serum ureal nitrogen level
Time Frame: every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
Serum creatinin level
Time Frame: every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
fasting blood glucose level
Time Frame: every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
blood electrolytes level(K+, Na+,Cl-,Ca2+,Mg2+)
Time Frame: every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every 3 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
blood LDH level
Time Frame: every 6 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every 6 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
QTc from ECG
Time Frame: every 6 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
every 6 weeks though study completion,from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Sunyat-senU201602101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Extranodal NK-T-Cell
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
Samsung Medical CenterCompletedExtranodal NK/T Cell LymphomaKorea, Republic of
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedExtranodal NK/T-cell Lymphoma, Nasal TypeChina
-
The Affiliated Hospital of Xuzhou Medical UniversityRecruitingNK-Cell Leukemia | Extranodal NK T Cell LymphomaChina
-
Ruijin HospitalUnknownNasal Type Extranodal NK/T-Cell LymphomaChina
-
Sun Yat-sen UniversityEli Lilly and Company; Hoffmann-La RocheUnknownExtranodal NK/T-cell Lymphoma, Nasal TypeChina
-
Fudan UniversityTerminatedExtranodal NK/T-cell Lymphoma, Nasal TypeChina
-
Beijing Tongren HospitalNot yet recruitingExtranodal NK/T-cell Lymphoma, Nasal Type
-
Jiangsu HengRui Medicine Co., Ltd.UnknownExtranodal NK/T-cell Lymphoma, Nasal TypeChina
Clinical Trials on Chidamide BIW
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Lee's Pharmaceutical LimitedUnknown
-
Kyowa Kirin Korea Co., Ltd.TerminatedPhase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma | Phase 2 Portion : Small Cell Lung Cancer(SCLC)Korea, Republic of
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
Sun Yat-sen UniversityRecruitingTriple Negative Breast CancerChina
-
Sun Yat-sen UniversityUnknown
-
Kyowa Hakko Kirin Pharma, Inc.TerminatedMultiple MyelomaUnited States
-
Zhejiang UniversityRecruitingT Lymphoblastic Leukemia/LymphomaChina
-
Sichuan UniversityRecruiting
-
Cancer Institute and Hospital, Chinese Academy...UnknownNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina